Page last updated: 2024-10-31

modafinil and HIV Coinfection

modafinil has been researched along with HIV Coinfection in 7 studies

Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.

Research Excerpts

ExcerptRelevanceReference
"To evaluate the efficacy and safety of modafinil in the treatment of fatigue in patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) and to assess effect on depressive symptoms."9.14Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. ( McElhiney, MC; McGrath, PJ; Rabkin, JG; Rabkin, R, 2010)
"This pilot study shows encouraging results for modafinil in alleviation of fatigue in HIV+ patients."9.11Modafinil treatment for fatigue in HIV+ patients: a pilot study. ( Ferrando, SJ; McElhiney, MC; Rabkin, JG; Rabkin, R, 2004)
"Fatigue is prevalent among patients with hepatitis C virus (HCV) and with HIV/AIDS but there are no established fatigue treatments for either condition or their combination."6.76Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C. ( McElhiney, MC; Rabkin, JG; Rabkin, R, 2011)
"To evaluate the efficacy and safety of modafinil in the treatment of fatigue in patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) and to assess effect on depressive symptoms."5.14Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. ( McElhiney, MC; McGrath, PJ; Rabkin, JG; Rabkin, R, 2010)
"This pilot study shows encouraging results for modafinil in alleviation of fatigue in HIV+ patients."5.11Modafinil treatment for fatigue in HIV+ patients: a pilot study. ( Ferrando, SJ; McElhiney, MC; Rabkin, JG; Rabkin, R, 2004)
"HIV+ participants with fatigue were treated with armodafinil."3.91Returning to work after fatigue treatment and counseling in HIV/AIDS. ( Daughters, SB; McElhiney, MC; Rabkin, JG; Timperlake, EC; Wainberg, ML, 2019)
"Fatigue is prevalent among patients with hepatitis C virus (HCV) and with HIV/AIDS but there are no established fatigue treatments for either condition or their combination."2.76Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C. ( McElhiney, MC; Rabkin, JG; Rabkin, R, 2011)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
McElhiney, MC5
Rabkin, JG5
Daughters, SB1
Timperlake, EC1
Wainberg, ML1
McElhiney, M2
Rabkin, J2
Van Gorp, W2
Rabkin, R6
Nunes, EV1
McGrath, PJ1
Ferrando, SJ1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS[NCT01158443]Phase 446 participants (Actual)Interventional2010-07-31Completed
Modafinil Treatment for Fatigue in HIV+ Patients[NCT00118378]Phase 4115 participants (Actual)Interventional2004-12-31Completed
Armodafinil Treatment for Fatigue in HIV+ Patients[NCT00737204]Phase 470 participants (Actual)Interventional2008-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

CD4 Cell Count

CD4 cell count is a laboratory marker providing an indication of immune functioning. Blood was drawn for this measure at baseline and week 4. The reference range for CD4 cell count is 490-1740, and a clinically significant change is defined as a change of >= 100 cells. A higher number is associated with better immune functioning. (NCT00118378)
Timeframe: Measured at baseline and Week 4

,
InterventionCells/mcL (Mean)
Baseline CD4 cell countWeek 4 CD4 cell count
Modafinil481466
Placebo459482

Fatigue Severity Scale (FSS)

The FSS is a 9-item self-report scale that measures the impact of fatigue on everyday functioning. Each item is rated on a scale of 1 to 7. Total scores range from 9 to 63, with a higher value indicating greater impairment due to fatigue. (NCT00118378)
Timeframe: Measured at baseline and Week 4

,
Interventionunits on a scale (Mean)
Baseline FSSWeek 4 FSS
Modafinil5234
Placebo5243

HIV RNA Viral Load

"HIV RNA viral load assay is a laboratory measure indicating viral activity. Because of the large range of possible values (50-100,000 copies), this measure is presented in log10. We entered the log10 value of 1.69 when the laboratory result stated under 50 copies, which was the assay's lowest limit of detectability during the study." (NCT00118378)
Timeframe: Measured at baseline and Week 4

,
InterventionLog10 copies/mL (Mean)
Baseline Log10 Viral LoadWeek 4 Log10 Viral load
Modafinil2.532.31
Placebo2.412.30

Role Function Scale Outcome

The Role Function Scale includes 10 items drawn from the Short Form 36-item Health Survey (SF-36) and other SF versions. It is intended to assess the extent to which fatigue has a behavioral impact on daily activities. Scores of frequency in the past week, on a 5-point scale, are summed with higher scores signifying greater role impairment. Scores range from 10 to 50. (NCT00118378)
Timeframe: Measured at baseline and Week 4

,
Interventionunits on a scale (Mean)
Baseline Role Function ScaleWeek 4 Role Function Scale
Modafinil3922
Placebo3627

CD4 Cell Count

Cd4 cell count is a laboratory marker providing an indication of immune system functioning. Blood samples were drawn for this measure at baseline and week 4. The reference range for CD4 cell count is 490-1740, and a clinically significant change is defined as a change of >=100 cells. A higher number is associated with better immune functioning. (NCT00737204)
Timeframe: Measured at baseline and Week 4

,
InterventionCells/mcL (Mean)
Baseline CD4 cell countWeek 4 CD4 cell count
Armodafinil502503
Placebo450445

Fatigue Severity Scale(FSS) Outcome

The FSS is a 9-item self-report scale that measures the impact of fatigue on everyday functioning. Each item is rated on a scale of 1 to 7. Total scores range from 9-63, with a higher score indicating greater impairment due to fatigue. (NCT00737204)
Timeframe: Measured at baseline and Weeks 4

,
Interventionunits on a scale (Mean)
Baseline FSSWeek 4 FSS
Armodafinil52.625.8
Placebo53.139.4

HIV Viral Load

"HIV RNA viral load assay is a laboratory measure indicating viral activity. Because of the large range of possible values (50 - 100,000 copies), this measure is transformed to log10 values. We entered the log10 value of 1.69 when the laboratory result stated under 50 copies, which was the assay's lowest limit of detectability during the study." (NCT00737204)
Timeframe: Measured at baseline and Week 4

,
InterventionLog10 copies/mL (Mean)
Baseline Log10 Viral LoadWeek 4 Log10 Viral load
Armodafinil2.172.15
Placebo2.392.24

Role Function Scale

The Role Function Scale includes 10 items drawn from the Short Form 36-item Survey (SF-36) and other SF versions. It is intended to assess the extent to which fatigue has a behavioral impact on daily activities. Scores of frequency in the past week, on a 5-point scale, are summed with higher scores signifying greater role impairment. Scores range from 10-50. (NCT00737204)
Timeframe: Measured at Baseline and Week 4

,
Interventionunits on a scale (Mean)
Baseline Role Function ScaleWeek 4 Role Function Scale
Armodafinil36.219.9
Placebo37.828.3

Trials

5 trials available for modafinil and HIV Coinfection

ArticleYear
Effect of armodafinil on cognition in patients with HIV/AIDS and fatigue.
    Journal of clinical and experimental neuropsychology, 2013, Volume: 35, Issue:7

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Benzhydryl Compounds; CD4 Lymphocyte Count; Central

2013
Modafinil effects on cognitive function in HIV+ patients treated for fatigue: a placebo controlled study.
    Journal of clinical and experimental neuropsychology, 2010, Volume: 32, Issue:5

    Topics: Adult; Aged; Analysis of Variance; Benzhydryl Compounds; CD4 Antigens; Central Nervous System Stimul

2010
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.
    The Journal of clinical psychiatry, 2010, Volume: 71, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 L

2010
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.
    The Journal of clinical psychiatry, 2010, Volume: 71, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 L

2010
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.
    The Journal of clinical psychiatry, 2010, Volume: 71, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 L

2010
Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.
    The Journal of clinical psychiatry, 2010, Volume: 71, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 L

2010
Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C.
    International journal of STD & AIDS, 2011, Volume: 22, Issue:2

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Female; H

2011
Modafinil treatment for fatigue in HIV+ patients: a pilot study.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:12

    Topics: Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 Lymphocyte Count; Central Nervous Sys

2004
Modafinil treatment for fatigue in HIV+ patients: a pilot study.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:12

    Topics: Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 Lymphocyte Count; Central Nervous Sys

2004
Modafinil treatment for fatigue in HIV+ patients: a pilot study.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:12

    Topics: Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 Lymphocyte Count; Central Nervous Sys

2004
Modafinil treatment for fatigue in HIV+ patients: a pilot study.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:12

    Topics: Adult; Aged; Anti-Retroviral Agents; Benzhydryl Compounds; CD4 Lymphocyte Count; Central Nervous Sys

2004

Other Studies

2 other studies available for modafinil and HIV Coinfection

ArticleYear
Returning to work after fatigue treatment and counseling in HIV/AIDS.
    Work (Reading, Mass.), 2019, Volume: 64, Issue:4

    Topics: Adult; Behavior Therapy; Counseling; Fatigue; Female; HIV Infections; Humans; Male; Middle Aged; Mod

2019
Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: a pilot study.
    The American journal of drug and alcohol abuse, 2009, Volume: 35, Issue:1

    Topics: Adult; Behavior Therapy; Benzhydryl Compounds; Combined Modality Therapy; HIV Infections; Homosexual

2009